[The effectiveness of the hypolipemic preparation lovastatin in patients with ischemic heart disease and hyperlipoproteinemia].
Lovastatin was investigated in a single-blind placebo-controlled trial in 150 patients with coronary atherosclerosis confirmed by coronary angiographic studies and those with nonfamilial hyperlipoproteinemia. After 3 months of treatment total cholesterol (TC) level was reduced by 36% (p less than 0.001), LDL cholesterol level by 48% (p less than 0.001), triglycerides level by 19% (p less than 0.001), VLDL cholesterol by 24% (p less than 0.01), whereas the HDL-cholesterol level was increased by 36% (p less than 0.001). Besides, concentration of apolipoprotein A-I increased by 19% (p less than 0.05), apolipoprotein B decreased by 22% (p less than 0.05) and the ratios of LDL cholesterol/HDL cholesterol and TC/HDL cholesterol decreased by 64% and 56%, respectively (p less than 0.001). The side effects of lovastatin were negligible. Thus, lovastatin is a highly effective and well tolerated hypolipidemic drug for the treatment of patients with IHD and hyperlipoproteinemia.
Iurenev
A P
AP
Zhukova
I M
IM
Lediashova
G A
GA
Kiseleva
O A
OA
Pomerantsev
E V
EV
D000328:Adult; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged
D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin
Izuchenie éffektivnosti gipolipidemicherskogo preparata lovastatina u bol'nykh ishemicheskoĭ bolezn'iu serdtsa i giperlipoproteidemieĭ.